Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
about
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathwayAbiraterone in metastatic prostate cancer without previous chemotherapyEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerAbiraterone in prostate cancer: a new angle to an old problemThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceHedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate CancerAbiraterone and increased survival in metastatic prostate cancerAndrogen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Update on options for treatment of metastatic castration-resistant prostate cancerA multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer.MDV3100 for the treatment of prostate cancer.Metastatic castration-resistant prostate cancer: critical review of enzalutamide.Novel drugs targeting the androgen receptor pathway in prostate cancer.Metastatic castration-resistant prostate cancer: two case reports of dramatic response with abiraterone acetate in patients heavily pretreated with chemotherapy.The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancerAndrogen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone TreatmentLimited expression of cytochrome p450 17α-hydroxylase/17,20-lyase in prostate cancer cell linesNovel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate CancerAbiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerCastration-resistant prostate cancer: mechanisms, targets, and treatment.Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasionCurrent paradigms and evolving concepts in metastatic castration-resistant prostate cancer.Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerThe changing landscape in the treatment of metastatic castration-resistant prostate cancer.Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implicationsAndrogen receptor: role and novel therapeutic prospects in prostate cancer.Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation.New therapies for castrate-resistant prostate cancer.Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel settingA new era for castrate resistant prostate cancer: a treatment review and update.The role of abiraterone in the management of metastatic castration-resistant prostate cancer.The role of enzalutamide in the treatment of castration-resistant prostate cancer.Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.New agents in the arsenal to fight castrate-resistant prostate cancer.Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
P2860
Q24603649-BE07A7DF-82F5-417A-9E61-39C3F46E8AEDQ24612084-AE4E8817-28F8-45A7-84B6-28F152FACC1FQ26777310-FC6C0F07-5DEE-4DB6-9304-F6D929BFE72DQ26828810-986AA622-E04C-41FA-BC22-ED77E6F815F2Q28076745-9FFADFFB-9FD4-4372-87EF-18C8C75DCFAEQ28277254-7125BA5C-EA54-4A2D-B9B7-9AAE4029BD82Q29617512-CEFD265E-17E8-4D18-8BCC-F935AA5B3F9CQ33621403-7F503DDA-D9D2-47E8-97F6-C0D304BFCF6CQ33956051-5F84F934-44D1-4C61-9B0D-65EEF6509B58Q34183632-7DF5E241-BA5F-4697-B536-F38896514872Q34245740-845E7A0D-F5E2-4C81-BF26-730DAC44E1AAQ34381852-A0F8F411-2C10-4490-AEC5-1AB2135D431CQ34395777-7A81E77B-212B-44B3-8B28-93A17A3C2BB0Q34880412-AB39135A-1604-4CDF-B057-A0035626692AQ34956110-EFBCD3B6-B938-4E85-BA7D-3CB2BF5D2849Q35037277-F3B88A5B-5B52-4407-9BAE-CBB38DEA77DDQ35152021-C257A304-C72A-4857-BCA6-1E09D87CCC4CQ35210730-83172061-8189-4E03-B807-BEBBA53D508BQ35358010-5528E9CA-06C6-463B-B7E8-6D726019D32AQ35584698-5CCD1204-91D2-4AFC-8840-7DADC69BB978Q35864027-919518AC-2F0B-4FA1-AC7F-AB21949E0D26Q35881896-DFDCF166-BC64-4C86-B7FC-DCCE417691DAQ35962274-B8E92E87-4056-4571-906C-2B4813421452Q36121693-1C72D2EF-089A-4C68-8CE8-118F0A97C830Q36253388-2E38D268-278B-4A8F-96CA-ECC14404314FQ36504117-46235D74-EA29-4B7A-90E7-7C2007744407Q36515526-475A29C0-102D-4210-974A-3C74D831DD59Q37098796-71467C03-9DFF-4726-81AA-2B74587F357DQ37159878-2BBCF808-F216-4D40-94D5-87AC1B04ECE4Q37256846-7E9DEFD7-1DFB-4E2D-8615-80DFBC8E3C26Q37469444-CD12F5C3-64AE-48EE-9EB2-606D15188C91Q37479334-2E5D453D-84DC-4710-8B12-75B429E0D075Q37887817-BF154D8A-C68B-4CC2-A173-9500A3B7B2BFQ37952048-4593A238-C9ED-4065-B1E4-72E96C45973BQ37985547-0160EA8B-F86B-4897-902B-98BCEAB19F07Q38002465-1D63E72A-4F6F-427D-87F8-B9516B63BEBBQ38048881-877A3B82-1119-455C-AF67-8E9BEF4817CEQ38078285-8A3394C0-0F9E-44E6-B1E4-7549BF729478Q38084606-44C3B62C-CA0F-4A91-B48F-E17841EF8E10Q38118056-6CBC94A5-4E73-463D-94B1-DB4DD6C5BFE7
P2860
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Selective blockade of androgen ...... ng metastatic prostate cancer.
@ast
Selective blockade of androgen ...... ng metastatic prostate cancer.
@en
Selective blockade of androgen ...... ng metastatic prostate cancer.
@nl
type
label
Selective blockade of androgen ...... ng metastatic prostate cancer.
@ast
Selective blockade of androgen ...... ng metastatic prostate cancer.
@en
Selective blockade of androgen ...... ng metastatic prostate cancer.
@nl
prefLabel
Selective blockade of androgen ...... ng metastatic prostate cancer.
@ast
Selective blockade of androgen ...... ng metastatic prostate cancer.
@en
Selective blockade of androgen ...... ng metastatic prostate cancer.
@nl
P2093
P2860
P1433
P1476
Selective blockade of androgen ...... ng metastatic prostate cancer.
@en
P2093
Arie S Belldegrun
Gerhardt Attard
Johann S de Bono
P2860
P304
P356
10.1111/J.1464-410X.2005.05821.X
P577
2005-12-01T00:00:00Z